For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human MMP-3 Detection Kit is designed for detection and quantitation of human MMP-3 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Matrix Metalloproteinase 3 (MMP3), also referred to as stromelysin-1, is a 378 amino acid zinc- and calcium-dependent protease expressed by fibroblasts, endothelial cells, macrophages, osteoblasts, chondrocytes, vascular smooth muscle cells, and keratinocytes. MMP3 is secreted as a pro-enzyme (pro-MMP3) and is activated by proteolytic cleavage by serine proteases such as plasmin. The substrates for MMP3 are collagen type III, IV and V, proteoglycans, laminin, fibronectin, fibrillin, osteopontin, and gelatin. MMP3 is mainly implicated in rheumatoid arthritis disease in which it is involved in degradation of connective tissue in the synovial joint. MMP3 levels increased in serum in patients with rheumatoid arthritis disease, osteoarthritis of the hip, and certain tumors.
|Assay Target Class||Protein|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Shipping Condition||Blue Ice|
|Unit Size||10,000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.